Unity Biotechnology Inc (UBX) concluded trading on Wednesday at a closing price of $1.33, with 0.46 million shares of worth about $0.61 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -8.28% during that period and on January 08, 2025 the price saw a loss of about -26.52%. Currently the company’s common shares owned by public are about 16.85M shares, out of which, 15.37M shares are available for trading.
Stock saw a price change of 36.21% in past 5 days and over the past one month there was a price change of 11.76%. Year-to-date (YTD), UBX shares are showing a performance of 36.21% which decreased to -30.37% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.94 but also hit the highest price of $2.02 during that period. The average intraday trading volume for Unity Biotechnology Inc shares is 116.14K. The stock is currently trading 16.26% above its 20-day simple moving average (SMA20), while that difference is up 11.24% for SMA50 and it goes to -5.99% lower than SMA200.
Unity Biotechnology Inc (NASDAQ: UBX) currently have 16.85M outstanding shares and institutions hold larger chunk of about 13.48% of that.
The stock has a current market capitalization of $22.41M and its 3Y-monthly beta is at 0.76. It has posted earnings per share of -$1.32 in the same period. It has Quick Ratio of 3.45 while making debt-to-equity ratio of 1.73. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for UBX, volatility over the week remained 25.09% while standing at 10.07% over the month.
Stock’s fiscal year EPS is expected to rise by 49.70% while it is estimated to increase by 16.60% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Rodman & Renshaw on August 22, 2024 offering a Buy rating for the stock and assigned a target price of $8 to it. Coverage by Wedbush stated Unity Biotechnology Inc (UBX) stock as an Outperform in their note to investors on November 16, 2023, suggesting a price target of $4 for the stock. On January 04, 2022, ROTH Capital Upgrade their recommendations, while on November 10, 2021, Mizuho Upgrade their ratings for the stock with a price target of $7. Stock get a Buy rating from Citigroup on June 28, 2021.
